Sign in to view Prof Dean A.’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Leicester, England, United Kingdom
Contact Info
Sign in to view Prof Dean A.’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
1K followers
500+ connections
Sign in to view Prof Dean A.’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Prof Dean A.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Prof Dean A.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Prof Dean A.’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Experience & Education
-
University of Leicester
********* ** ******** ******* ********
-
********** ********* ** ********* *** *****
********** *********, ******** ******* ********
-
***
** ** ********
-
***
***(**** *** *****)
View Prof Dean A.’s full experience
See their title, tenure and more.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View Prof Dean A.’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Other similar profiles
-
Samreen Ahmed
Professor of Medical Oncology
United KingdomConnect -
Jens Hahne
London Area, United KingdomConnect -
Salvador Macip
Medicine, Science and Writing
LeicesterConnect -
Robert Rintoul
Professor of Thoracic Oncology at University of Cambridge
Greater Cambridge AreaConnect -
John Edwards
Consultant Thoracic Surgeon
SheffieldConnect -
Puthen Veettil Jithesh PhD FRSB
Associate Dean for Education
QatarConnect -
Harriet Walter
Clinical Research Fellow Medical Oncology at University of Leicester
LeicesterConnect -
Sean Dulloo
--
United KingdomConnect -
Aleksandra Bzura
Postdoctoral Researcher - Cancer & Molecular Biology
LeicesterConnect -
Dean Fennell-Connell
HavantConnect -
Fennell, Dean (Prof.)
--
United KingdomConnect -
Joanna Działo
Postdoctoral Research Assistant w Leicester Cancer Research Centre
Greater Leicester AreaConnect -
Lorna Jarvis
Research Associate at University of Cambridge
United KingdomConnect -
Steven Albelda
Professor at University of Pennsylvania
Philadelphia, PAConnect -
bindu nair
lecturer at University
Thiruvananthapuram TalukConnect -
Neil Lawrence
Paediatrics Registrar and Clinical Academic
SheffieldConnect -
Brian Cunniff
Assistant Professor at The Robert Larner, M.D. College of Medicine at the University of Vermont
Burlington, VTConnect -
Peter Szlosarek
Professor at Barts Cancer Institute
Greater LondonConnect -
Ethan Dmitrovsky, MD
Laboratory Director, Frederick National Laboratory for Cancer Research President, Leidos Biomedical Research
Frederick, MDConnect -
Essam Abdelalim
Principal Investigator at Sidra Medicine and Joint Associate Professor at CHLS, HBKU, Qatar Foundation
Doha, QatarConnect
Explore more posts
-
PCSK9 Education and Research Forum
Could lerodalcibep be a useful alternative to other PCSK9 inhibitors for patients with CVD? Take a look at the results of the LIBerate-HR study, presented at ACC.24, reported on PCSK9 Forum >> https://lnkd.in/eVN948EW #ACC24 #PCSK9 #lerodalcibep #LiberateHR #CVD #PCSK9Forum Eric Klug
10 -
Brian Lipworth
Asthma + Lung UK Preventable Asthma Deaths Just a quick heads up that I will be doing a slot on BBC Scotland tonight at 21-31 BST on this important topic focussing on strategies to get on top of this problem Can watch this live on iplayer apparently if you live in England/Wales/NI -assuming you have a TV license Here is the link-its at 34 min into the programme -link expires at 2200 on 25th April -in any event all the relevant bits of info are given below https://lnkd.in/eXDmthdK I will be discussing various strategies to improve control and avoid deaths including: Education about asthma best done by nurses and pharmacists Employing a simple asthma action plan Ask pts to do am PEF diary three days a week ACT/ACQ whenever reviewed in primary care Spirometry and ideally FeNO on annual basis Ensuring optimal inhaler technique with a device the pt likes and can use properly Ensure prefect concordance between ICS and reliever with single inhaler -eg using BUD/FORM reliever as AIR/MART in keepign with GINA Making things simple with instructions using AIR/MART "use more when you need it less when you don't" -ie escalating/descalating between AIR/MART depending on prevailing triggers Address relevant triggers such as active/passive smoking ,polution, allergens ,occupational , premenstrual ,drugs (NSAID, beta-blockers ACEI)
644 Comments -
Laura Dormer
📢New article alert from the Journal of Comparative Effectiveness Research: Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review New systematic review investigates the six-minute walk test (6MWT) as an end point in cardiomyopathy trials. Identifying 41 relevant studies, the findings suggest a greater 6MWT distance is linked to a reduced risk of hospitalization or mortality, supporting its use as a key assessment in cardiomyopathy clinical trials, including transthyretin-mediated amyloidosis. Authors: Jose Nativi-Nicolau, Ali Yilmaz, Noel Dasgupta, Richard Macey, James Cochrane, Judith Peatman, Catherine Summers, Jennifer Luth & Ronald Zolty Mayo Clinic, Universitätsklinikum Münster, Indiana University School of Medicine, Adelphi Values, Alnylam Pharmaceuticals, University of Nebraska at Omaha #SystematicReview #Cardiomyopathy #ClinicalTrials #OpenAccess https://lnkd.in/eQg_e3Nw
8 -
Alex's Lemonade Stand Foundation
SPEAKER SERIES RETURNS TODAY (6/12): The Promise and Challenges of Dissecting Extracellular Vesicle (Exosome) Pathways in Diagnosis and Treatment of Childhood Cancers, with Dr. Janusz Rak Register > https://lnkd.in/ejdeqbdK This lecture will have four objectives: 🍋 Appreciate the role of liquid biopsy in cancer and the emerging role of this approach in pediatric malignancies. 🍋 Learn about the unique nature and complexities of exosomes and other subtypes of extracellular vesicles and particles as biological mediators and liquid biopsy analytes. 🍋 Reflect on the link between oncogenic transformation and extracellular vesicle landscapes in cancer, including inroads made in some pediatric malignancies. 🍋 Touch on the emerging technologies aiming to analyze extracellular vesicle populations for the purpose of discovery and liquid biopsy applications.
7 -
RLS Radiopharmacies
New research highlighted in The Journal of Nuclear Medicine - JNM found that PET/MRI combined with the PRIMARY scoring system could curb over 80% of unnecessary prostate biopsies. The Prostate Imaging Reporting and Data System (PI-RADS) offers a five-point scale to assess potential prostate cancer from images. Cases that fall into the ambiguous PI-RADS 3 category pose a real dilemma: should a patient undergo a biopsy? Presently, less than a fifth of these cases reveal significant cancer. However, it is important to note that forgoing biopsy could come at the expense of missing 12.5% of clinically significant prostate cancer cases. You can read more about the study in the April issue of JNM. https://lnkd.in/g8kcrmSm #ProstateCancer #DiagnosticImaging #PETMRI #NuclearMedicine
541 Comment -
Manil Subesinghe
Happy to share our (Rohit Srinivasan, Gary Cook (MBBS MSc MD FRCR FRCP) Neel Patel) recently published pictorial review on non-prostatic benign and malignant diseases on PSMA PET-CT in Clinical Radiology (The Royal College of Radiologists) with cases from Guy's and St Thomas' NHS Foundation Trust, King's Faculty of Life Sciences & Medicine & Oxford University Hospitals NHS Foundation Trust. Multiple illustrative cases demonstrate that PSMA expression is not restricted to prostate cancer and that endothelial PSMA expression in the neovasculature most likely mechanism underpinning PSMA uptake in these diseases. Although these diseases add complexity to PSMA PET-CT reporting, there are potential diagnostic applications of PSMA PET-CT (in cases of limited FDG uptake) and exciting theranostic options to be explored in the future #nuclearmedicine #PETCT
29 -
Fen Guo, Ph.D., FACMG, FCCMG
I am delighted to share that our latest paper,"Beyond Single Diagnosis: Exploring Multidiagnostic Realities in Pediatric Patients through Genome Sequencing," has just been published. Our findings highlight the complexity of rare diseases and emphasize the importance of comprehensive, genome-level diagnostics. https://lnkd.in/evtRwvg8 #GenomeSequencing #PediatricResearch #GeneticDiagnosis #HumanMutation
651 Comment -
Genomics Education Programme
Why is #genomics important in #neurology and how is it being applied in a clinical setting? In our video, Professor Huw Morris outlines the increasing role of genomics and some of things neurologists should be aware of. View the full resource here: https://buff.ly/3vfmqWE
3 -
Hydrocephalus Society
We are pleased to present this month's interesting study, "Prediction of Surgical Outcomes in Normal Pressure Hydrocephalus by MR Elastography", authored by: Pragalv Karki, Matthew C Murphy, Petrice M Cogswell, Matthew L Senjem, Jonathan Graff-Radford, Benjamin D Elder, Avital Perry, Christopher S Graffeo, Fredic B Meyer, Clifford R Jack Jr, Richard L Ehman and John Huston 3rd. This study uses MR Elastography to predict surgical outcomes in Normal Pressure Hydrocephalus (NPH), offering a noninvasive alternative to traditional methods. Results suggest improved NPH diagnostic odds ratio and positive predictive value. This advancement could significantly improve the management of Normal Pressure Hydrocephalus, impacting the lives of those affected by this condition. 📑Read the Full Paper here: https://lnkd.in/dPJDyBuW
29 -
LitGrab
Cutaneous Leishmaniasis https://lnkd.in/er-BYKSx 10.3390/pharmacy12010030 CUTANEOUS LEISHMANIASIS - eight countries 90% of CL cases: Afghanistan, Algeria, Brazil, Iran, Pakistan, Peru, Saudi Arabia, and Syria - L. tropica and L. major usually self-heal within a year but leave permanent scars - L. aethiopica takes years to heal and can develop into severe oral–nasal MCL and diffuse forms of CL, scarring can result in aesthetic impairment - L. major, exclusively induce cutaneous manifestations, can self-heal but with scarring - L. tropica, predominantly CL, but may rarely progress to VL Several treatment options for CL are available - thermotherapy and cryotherapy are non-selective treatments - intra-lesion or systemic pentavalent antimonials (e.g., pentostam) involves injecting 1–3 mL under and around the lesion, repeat injections every 5–7 days, totalling 2–5 times - 72–97% of lesions caused by L. major may resolve - Synthesized nitric oxide-releasing chitosan nanoparticles (NONPs) showed potential in vitro activity against L. amazonensis - 15% paromomycin-containing cream incorporating 12% methyl benzethonium chloride. Irritation associated with methyl benzethonium chloride (observed in up to 75% of patients) - Topical liposomal amphotericin B (LAmB) is not commonly available - Pentavalent antimonials (sodium stibogluconate—Pentostam®️ or meglumine antimoniate—Glucantime®️) - Miltefosine - Pentamidine
1 -
Institute for Health Metrics and Evaluation
NEW—GBD 2021 is the first iteration of the GBD published in the @TheLancet where we have profiled the related Burden of Proof studies, examining a ⭐ new star rating ⭐ for the strength of evidence on the relationship between risks and specific outcomes, such as: 🚭 smoking and lung cancer 🥦 diet low in vegetables and type 2 diabetes 🩸 high systolic blood pressure and ischemic heart disease Interested in learning more? Check out the GBD 2021 overview ➭ http://ms.spr.ly/6041YkfCb
551 Comment
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More